The Board of the Neurology Support Centre (NSC) in Sligo has confirmed that the charity is preparing to wind-down after 13 ...

NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms ...

Orthogon Therapeutics today announced the closing of a follow-on $11 million financing, bringing its total capital raised to ...

Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 monthsTop-line data expected year-end ...

Filing acceptance based on Phase III ALLEGORY data for Gazyva showing a significant reduction in disease activity compared with placebo in people with systemic lupus erythematosus (SLE)If approved, ...

Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple ...

Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 months Top-line data expected year-end 2026/ first quarter 2027 NEW YORK, April 15, 2026 (GLO ...

Sixth paragraph, fifth sentence of release issued April 20, 2026 at 10 p.m. PT/April 21, 2026 at 1 a.m. ET, should read: In addition, treatment with Gazyva plus standard therapy, versus placebo plus ...

Author Trevis Gleason reflects on two decades of writing about MS, from clinical research to personal milestones. Discover how a simple blog evolved into a global community.

Learn how eyeglass lens replacement works without changing your frames. Explore relensing options, lens types, coatings, ...

Progressive’s real advantage is its disciplined, data-driven approach to pricing insurance. As the cycle turns, the car insurer may not be able to keep all of the market share gains it picked up last ...